Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada
Danuta M Skowronski, Solmaz Setayeshgar, Yossi Febriani, Manale Ouakki, Macy Zou, Denis Talbot, Natalie Prystajecky, John R Tyson, Rodica Gilca, Nicholas Brousseau, Geneviève Deceuninck, Eleni Galanis, Chris D Fjell, Hind Sbihi, Elise Fortin, Sapha Barkati, Chantal Sauvageau, Monika Naus, David M Patrick, Bonnie Henry, Linda M N Hoang, Philippe De Wals, Christophe Garenc, Alex Carignan, Mélanie Drolet, Manish Sadarangani, Marc Brisson, Mel Krajden, Gaston De Serres
doi: https://doi.org/10.1101/2021.10.26.21265397
Danuta M Skowronski
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
Solmaz Setayeshgar
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
Yossi Febriani
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
Manale Ouakki
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
Macy Zou
5BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada
Denis Talbot
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Natalie Prystajecky
7BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
8University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
John R Tyson
7BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
8University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
Rodica Gilca
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Nicholas Brousseau
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Geneviève Deceuninck
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
Eleni Galanis
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
Chris D Fjell
7BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
Hind Sbihi
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
5BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada
Elise Fortin
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
Sapha Barkati
9McGill University, Department of Medicine, Division of Infectious Diseases, McGill University Health Center, Montreal, Quebec, Canada
Chantal Sauvageau
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Monika Naus
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
David M Patrick
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
Bonnie Henry
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
10Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada
Linda M N Hoang
7BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
8University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
Philippe De Wals
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Christophe Garenc
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
Alex Carignan
11Sherbrooke University, Department of Microbiology and Infectious Diseases, Sherbrooke, Quebec, Canada
Mélanie Drolet
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Manish Sadarangani
12BC Children’s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada
13University of British Columbia, Department of Pediatrics, Vancouver, British Columbia, Canada
Marc Brisson
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Mel Krajden
7BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
8University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
Gaston De Serres
3Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, Quebec, Canada
4Institut national de sante publique du Québec, Biological and Occupational Risks, Quebec City, Quebec, Canada
6Laval University, Department of Social and Preventive Medicine, Faculty of Medicine, Quebec City, Quebec, Canada
Article usage
Posted October 26, 2021.
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada
Danuta M Skowronski, Solmaz Setayeshgar, Yossi Febriani, Manale Ouakki, Macy Zou, Denis Talbot, Natalie Prystajecky, John R Tyson, Rodica Gilca, Nicholas Brousseau, Geneviève Deceuninck, Eleni Galanis, Chris D Fjell, Hind Sbihi, Elise Fortin, Sapha Barkati, Chantal Sauvageau, Monika Naus, David M Patrick, Bonnie Henry, Linda M N Hoang, Philippe De Wals, Christophe Garenc, Alex Carignan, Mélanie Drolet, Manish Sadarangani, Marc Brisson, Mel Krajden, Gaston De Serres
medRxiv 2021.10.26.21265397; doi: https://doi.org/10.1101/2021.10.26.21265397
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada
Danuta M Skowronski, Solmaz Setayeshgar, Yossi Febriani, Manale Ouakki, Macy Zou, Denis Talbot, Natalie Prystajecky, John R Tyson, Rodica Gilca, Nicholas Brousseau, Geneviève Deceuninck, Eleni Galanis, Chris D Fjell, Hind Sbihi, Elise Fortin, Sapha Barkati, Chantal Sauvageau, Monika Naus, David M Patrick, Bonnie Henry, Linda M N Hoang, Philippe De Wals, Christophe Garenc, Alex Carignan, Mélanie Drolet, Manish Sadarangani, Marc Brisson, Mel Krajden, Gaston De Serres
medRxiv 2021.10.26.21265397; doi: https://doi.org/10.1101/2021.10.26.21265397
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)